查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1701653

人類乳突病毒 (HPV) 檢測市場：全球產業分析、規模、佔有率、成長、趨勢和預測（2025-2032年）

Human Papillomavirus (HPV) Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 192 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

主要調查結果

  • HPV檢測市場規模：14億美元（2025年）
  • 預計市值：28.163億美元（2032年）
  • 全球市場成長率：10.5%（2025-2032年的年複合成長率）

HPV檢測市場 - 報告範圍

HPV檢測是子宮頸癌篩檢和預防計畫的重要組成部分。這些測試可以檢測出與子宮頸癌發展相關的高危險 HPV 株的存在。該市場面向醫院、診斷實驗室和診所，並透過 PCR、混合捕獲和次世代定序（NGS）等各種平台提供基於 DNA 和 mRNA 的檢測選項。人們對 HPV 與子宮頸癌之間關聯的認知不斷提高，加上政府提倡定期篩檢，大幅推動了市場的成長。早期診斷需求的不斷成長、新興地區醫療基礎設施的不斷擴大以及 HPV 檢測被納入國家篩檢指南，進一步推動了市場擴張。

市場成長動力

全球 HPV 檢測市場主要受到全球 HPV 感染率上升和子宮頸癌發生率上升的推動。政府的優惠政策和宣傳宣傳活動提倡定期篩檢和早期發現，提高了患者的依從性和篩檢率。自採集試劑套件、液基細胞學和高靈敏度分子診斷的發展等技術進步徹底改變了 HPV 檢測，提供了更高的準確性和便利性。此外，人們對女性健康的關注度日益提高，尤其是在中低收入國家，這推動了對價格實惠、易於取得的HPV 篩檢工具的需求。公共衛生機構和診斷公司的合作在擴大HPV檢測服務方面也發揮了重要作用。

市場限制

儘管市場動能良好，HPV 檢測仍面臨若干挑戰。高昂的檢測成本仍然是廣泛採用的主要障礙，尤其是在新興經濟體。在農村和服務不足的地區，獲得先進診斷工具的機會有限，醫療保健基礎設施不發達進一步阻礙了市場滲透。此外，文化障礙、性健康的恥辱感以及某些領域缺乏意識也阻礙了患者參與篩檢計畫。此外，監管障礙和新診斷技術核准的延遲也給製造商和醫療保健提供者帶來了挑戰。透過教育、公共衛生投資和創新交付模式解決這些問題對於市場的持續成長非常重要。

市場機會

HPV 檢測市場提供了巨大的機會，尤其是隨著家用檢測套組和自我採集方法的出現，它們提供了便利性並增加了患者的參與度。數位健康平台和遠端醫療服務的整合進一步推動了病人參與並改善了後續護理。預計照護現場診斷的進步和人工智慧主導的診斷演算法的使用將提高測試的準確性和解釋能力。 HPV 檢測的應用範圍也將擴大，不再局限於子宮頸癌篩檢，而是擴展到頭頸癌診斷應用，這也將為市場帶來益處。戰略夥伴關係、研發投資以及針對不同人群的客製化檢測解決方案有望成為充分發揮市場潛力和滿足未滿足的臨床需求的關鍵。

本報告研究了全球人類乳突病毒（HPV）檢測市場，並對市場動態進行了詳細分析，包括成長動力、趨勢、機會和挑戰。

目錄

第1章 執行摘要

第2章 市場概述

  • 市場範圍和定義
  • 市場動態
    • 促進因素
    • 限制因素
    • 機會
    • 課題
    • 主要趨勢
  • 宏觀經濟因素
    • 全球產業展望
    • 全球GDP成長前景
  • COVID-19影響分析
  • 預測因子－相關性和影響力

第3章 增值考察

  • 監管格局
  • 產品採用分析
  • 價值鏈分析
  • 重大交易及合併
  • PESTLE分析
  • 波特五力分析

第4章 全球人類乳突病毒（HPV）檢測市場展望

  • 主要亮點
    • 市場規模及與前一年同期比較
    • 絕對的商機
  • 市場規模分析與預測
    • 市場規模表現分析（2019-2024）
    • 當前市場規模分析與預測（2025-2032）
  • 全球人類乳突病毒（HPV）檢測市場展望：產品
    • 簡介/主要調查結果
    • 市場規模實績分析：依產品（2019-2024年）
    • 目前市場規模分析及預測：依產品（2025-2032）
    • 市場吸引力分析：產品
  • 全球人類乳突病毒（HPV）檢測市場展望：應用
    • 簡介/主要調查結果
    • 市場規模實績分析：依應用（2019-2024）
    • 目前市場規模分析及預測：依應用（2025-2032）
    • 市場吸引力分析：應用
  • 全球人類乳突病毒（HPV）檢測市場展望：最終用戶
    • 簡介/主要調查結果
    • 市場規模實績分析：依最終用戶（2019-2024年）
    • 目前市場規模分析及預測：依最終用戶（2025-2032）
    • 市場吸引力分析：最終用戶

第5章 全球人類乳突病毒（HPV）檢測市場展望：依地區

  • 主要亮點
  • 市場規模實績分析：依地區（2019-2024）
  • 目前市場規模分析及預測：依地區（2025-2032）
    • 北美洲
    • 歐洲
    • 東亞
    • 南亞和大洋洲
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：地區

第6章 北美人類乳突病毒（HPV）檢測市場展望

第7章 歐洲人類乳突病毒（HPV）檢測市場展望

第8章 東亞人類乳突病毒（HPV）檢測市場展望

第9章 南亞和大洋洲人類乳突病毒（HPV）檢測市場展望

第10章 拉丁美洲人類乳突病毒（HPV）檢測市場展望

第11章 中東與非洲人類乳突病毒（HPV）檢測市場展望

第12章 競爭格局

  • 市場佔有率分析（2025年）
  • 市場結構
    • 競爭強度圖：依市場
    • 競爭儀錶板
  • 公司簡介（詳情－概述、財務狀況、策略、最新發展）
    • F. Hoffmann-La Roche Ltd.
    • Agilent Technologies, Inc.
    • Becton, Dickinson and Company
    • Qiagen NV
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • Hologic Inc.
    • Cepheid Inc.
    • Seegene Inc.
    • Takara Bio Inc.
    • DaAn Gene Co., Ltd. of Sun Yat-Sen University
    • Promega Corporation
    • Greiner Bio-One International GmbH（Greiner Holding AG）
    • Enzo Biochem Inc.
    • Norgen Biotek Corp.
    • DiagCor Bioscience Inc Ltd
    • Hybribio Limited
    • Zytovision GmbH
    • Arbor Vita Corporation
    • Medical & Biological Laboratories Co., Ltd
    • Fujirebio Diagnostics, Inc.

第13章 附錄

簡介目錄
Product Code: PMRREP11737

Persistence Market Research has recently released a comprehensive report on the worldwide market for Human Papillomavirus (HPV) testing. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global HPV testing market from 2025 to 2032.

Key Insights:

  • HPV Testing Market Size (2025E): US$ 1,400 Mn
  • Projected Market Value (2032F): US$ 2,816.3 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032):10.5%

HPV Testing Market - Report Scope:

HPV testing is a critical component of cervical cancer screening and prevention programs. These tests detect the presence of high-risk HPV strains associated with the development of cervical cancer. The market caters to hospitals, diagnostic laboratories, and clinics, offering both DNA-based and mRNA-based testing options through various platforms including PCR, hybrid capture, and next-generation sequencing (NGS). The growing awareness about HPV and its link to cervical cancer, coupled with government initiatives promoting routine screening, is significantly propelling market growth. Rising demand for early diagnosis, expanding healthcare infrastructure in emerging regions, and the integration of HPV testing into national screening guidelines further boost market expansion.

Market Growth Drivers:

The global HPV testing market is primarily driven by the increasing prevalence of HPV infections and the rising incidence of cervical cancer worldwide. Favorable government policies and awareness campaigns advocating for routine screening and early detection have improved patient compliance and screening rates. Technological advancements such as the development of self-sampling kits, liquid-based cytology, and high-sensitivity molecular diagnostics are revolutionizing the HPV testing landscape, offering better accuracy and convenience. Furthermore, the growing focus on women's health, especially in low- and middle-income countries, is generating demand for affordable and accessible HPV screening tools. Collaborations between public health organizations and diagnostic companies are also playing a pivotal role in expanding the reach of HPV testing services.

Market Restraints:

Despite positive market momentum, several challenges persist in the HPV testing landscape. High test costs, particularly in developing economies, remain a significant barrier to widespread adoption. Limited access to advanced diagnostic tools and underdeveloped healthcare infrastructure in rural and underserved areas further hamper market penetration. Additionally, cultural barriers, stigma associated with sexual health, and lack of awareness in certain regions hinder patient participation in screening programs. Regulatory hurdles and delays in the approval of new diagnostic technologies also pose challenges for manufacturers and healthcare providers alike. Addressing these issues through education, public health investment, and innovative delivery models is crucial for sustainable market growth.

Market Opportunities:

The HPV testing market presents significant opportunities, particularly with the emergence of home-based testing kits and self-sampling methods that increase convenience and patient participation. Integration of digital health platforms and telemedicine services is further facilitating patient engagement and improving follow-up care. Advances in point-of-care diagnostics and the use of AI-driven diagnostic algorithms are expected to enhance test accuracy and interpretation. The market also stands to benefit from the expansion of HPV testing beyond cervical cancer screening, including applications in head and neck cancer diagnostics. Strategic partnerships, investments in R&D, and customized testing solutions for diverse population groups will be key to unlocking the full market potential and addressing unmet clinical needs.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the HPV testing market globally?
  • Which testing technologies and platforms are gaining traction across various regions?
  • How are innovations such as self-sampling and AI impacting the HPV diagnostics field?
  • Who are the key players in the HPV testing market, and what strategies are they employing to stay competitive?
  • What are the emerging trends and future opportunities in the global HPV testing landscape?

Competitive Intelligence and Business Strategy:

Leading players in the global HPV testing market, including QIAGEN N.V., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, and Hologic, Inc., are focused on innovation, geographic expansion, and product portfolio diversification. These companies are investing heavily in the development of high-throughput, user-friendly testing platforms that meet international screening guidelines. Collaborations with national health programs, NGOs, and global health organizations enable these players to enhance accessibility in low-resource settings. Mergers and acquisitions, strategic licensing agreements, and regional distribution partnerships also help strengthen market presence. Companies are increasingly emphasizing awareness-building campaigns and educational initiatives to drive demand and improve health outcomes related to HPV-associated diseases.

Key Companies Profiled:

  • QIAGEN N.V.
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Becton, Dickinson and Company
  • Seegene, Inc.
  • Arbor Vita Corporation
  • bioMerieux SA
  • Thermo Fisher Scientific, Inc.
  • Cepheid (a Danaher Company)
  • NURX, Inc.

Human Papillomavirus (HPV) Testing Market Segmentation

By Product

  • DNA-based Test
  • RNA-based Test

By Application

  • Molecular Diagnostics
  • Research Use

By End User

  • Hospitals
  • Clinics
  • Diagnostics Centers
  • Research Institutes

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Human Papillomavirus Testing Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Human Papillomavirus Testing Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Human Papillomavirus Testing Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. DNA-based Test
      • 4.3.3.2. RNA-based Test
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Human Papillomavirus Testing Market Outlook: Application
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
      • 4.4.3.1. Molecular Diagnostics
      • 4.4.3.2. Research Use
    • 4.4.4. Market Attractiveness Analysis: Application
  • 4.5. Global Human Papillomavirus Testing Market Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.5.3.1. Hospitals
      • 4.5.3.2. Clinics
      • 4.5.3.3. Diagnostic Centers
      • 4.5.3.4. Research Institutes
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global Human Papillomavirus Testing Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Human Papillomavirus Testing Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Application
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. DNA-based Test
    • 6.4.2. RNA-based Test
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 6.5.1. Molecular Diagnostics
    • 6.5.2. Research Use
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.6.1. Hospitals
    • 6.6.2. Clinics
    • 6.6.3. Diagnostic Centers
    • 6.6.4. Research Institutes
  • 6.7. Market Attractiveness Analysis

7. Europe Human Papillomavirus Testing Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Application
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. DNA-based Test
    • 7.4.2. RNA-based Test
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 7.5.1. Molecular Diagnostics
    • 7.5.2. Research Use
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.6.1. Hospitals
    • 7.6.2. Clinics
    • 7.6.3. Diagnostic Centers
    • 7.6.4. Research Institutes
  • 7.7. Market Attractiveness Analysis

8. East Asia Human Papillomavirus Testing Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Application
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. DNA-based Test
    • 8.4.2. RNA-based Test
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 8.5.1. Molecular Diagnostics
    • 8.5.2. Research Use
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.6.1. Hospitals
    • 8.6.2. Clinics
    • 8.6.3. Diagnostic Centers
    • 8.6.4. Research Institutes
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Human Papillomavirus Testing Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Application
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. DNA-based Test
    • 9.4.2. RNA-based Test
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 9.5.1. Molecular Diagnostics
    • 9.5.2. Research Use
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.6.1. Hospitals
    • 9.6.2. Clinics
    • 9.6.3. Diagnostic Centers
    • 9.6.4. Research Institutes
  • 9.7. Market Attractiveness Analysis

10. Latin America Human Papillomavirus Testing Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Application
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. DNA-based Test
    • 10.4.2. RNA-based Test
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 10.5.1. Molecular Diagnostics
    • 10.5.2. Research Use
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.6.1. Hospitals
    • 10.6.2. Clinics
    • 10.6.3. Diagnostic Centers
    • 10.6.4. Research Institutes
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Human Papillomavirus Testing Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Application
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. DNA-based Test
    • 11.4.2. RNA-based Test
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 11.5.1. Molecular Diagnostics
    • 11.5.2. Research Use
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.6.1. Hospitals
    • 11.6.2. Clinics
    • 11.6.3. Diagnostic Centers
    • 11.6.4. Research Institutes
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. F. Hoffmann-La Roche Ltd.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Agilent Technologies, Inc.
    • 12.3.3. Becton, Dickinson and Company
    • 12.3.4. Qiagen N.V.
    • 12.3.5. Thermo Fisher Scientific Inc.
    • 12.3.6. Abbott Laboratories
    • 12.3.7. Hologic Inc.
    • 12.3.8. Cepheid Inc.
    • 12.3.9. Seegene Inc.
    • 12.3.10. Takara Bio Inc.
    • 12.3.11. DaAn Gene Co., Ltd. of Sun Yat-Sen University
    • 12.3.12. Promega Corporation
    • 12.3.13. Greiner Bio-One International GmbH (Greiner Holding AG)
    • 12.3.14. Enzo Biochem Inc.
    • 12.3.15. Norgen Biotek Corp.
    • 12.3.16. DiagCor Bioscience Inc Ltd
    • 12.3.17. Hybribio Limited
    • 12.3.18. Zytovision GmbH
    • 12.3.19. Arbor Vita Corporation
    • 12.3.20. Medical & Biological Laboratories Co., Ltd
    • 12.3.21. Fujirebio Diagnostics, Inc.

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations